{"name":"Abinopharm, Inc","slug":"abinopharm-inc","ticker":"","exchange":"","domain":"","description":"Abinopharm, Inc is a biotechnology company focused on the development and commercialization of novel therapeutics. The company currently markets Nicotinamide Mononucleotide, a compound with potential anti-aging properties.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Nicotinamide Mononucleotide","genericName":"Nicotinamide Mononucleotide","slug":"nicotinamide-mononucleotide","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Nicotinamide Mononucleotide","genericName":"Nicotinamide Mononucleotide","slug":"nicotinamide-mononucleotide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPV1hUcmVPQWpncTVwUmxhLXBlSkxnZU1GMzZnOWQtY3hCeFhTQWw0YlhaX1pwd0hkUTBXaFczeTgxWUg4SnlYd1J1UFFPdHVHVHpyeEU3V1pTcHVjV2k4X21mREZEOXhwc05mLUJfc2lQMDhEUEdxbGNuZEZ2cXBLb3ZXbkx3QWVvbDBxaQ?oc=5","date":"2026-02-02","type":"regulatory","source":"Yahoo Finance","summary":"Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence - Yahoo Finance","headline":"Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOUmNsVFdRU2xNMG45OVI1RnlRX29ESHVwZEdvcmo4QmdwemFqRWVuckZLcEUzQWFwdVhTVnMxWW52QXlVUE91NkN0M01JTGJSU0tTWkZwcG8zVlNFcnIyYVJUazVOdlBfZmU3X18wVDgtR0VhNHNDSVZHYWNZNjZHMExxQ21UVUU?oc=5","date":"2025-07-06","type":"trial","source":"Yahoo Finance","summary":"Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health - Yahoo Finance","headline":"Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin He","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPV0cxZ2xRZnVXOW1FYTJEM3hFakpCNkNTdWtZejh3bHI5TGZOc1RpRUVQRWxIbENkZ2xIcUZ5ZVczaDluSzJ3eTFoX3BfVkk4bmdOdFlRSVR4ZDZBcm04YkVIdXRKcnExS25yeGFmRkxCcF9YMDgtQkJIYzN4ZkM5d0VldDVjeXdobmZzTmM4bFJxR2s?oc=5","date":"2025-03-24","type":"regulatory","source":"Yahoo Finance","summary":"Abinopharm, Inc. warmly congratulates partner company EGT Synbio on receiving no objection letter from the FDA for their GRAS notification of Dr.Ergo®Ergothioneine - Yahoo Finance","headline":"Abinopharm, Inc. warmly congratulates partner company EGT Synbio on receiving no objection letter from the FDA for their","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}